Known targets — ChEMBL curated mechanism
ABL1ACEACHEACVR1ADRA1AADRA1BADRA1DADRA2AADRA2BADRA2CADRB1ADRB2ADRB3AGTR1ALKAVPR1AAVPR2BCHEBCRCA2CACNA1ACACNA1BCACNA1CCACNA1DCACNA1ECACNA1FCACNA1GCACNA1HCACNA1ICACNA1SCACNA2D1CACNA2D2CACNA2D3CACNA2D4CACNB1CACNB2CACNB3CACNB4CACNG1CACNG2CACNG3CACNG4CACNG5CACNG6CACNG7CACNG8CALCRLCASRCCR5CDK4CDK6CFBCHRM1CHRM2CHRM3CHRM4CHRM5CHRNA1CHRNA3CHRNA7CHRNB1CHRNB4CHRNDCHRNECHRNGCOXFA4COXFA4L2CRBNCSF1RCUL4ACYP19A1DDB1DPP4DRD1DRD2DRD3DRD4EDNRAEGFREML4ERBB2ERBB4ESR1ESR2FGFR1FGFR3FLT1FLT3FLT4GAAGABRA1GABRA2GABRA3GABRA4GABRA5GABRA6GABRB1GABRB2GABRB3GABRDGABREGABRG1GABRG2GABRG3GABRPGABRQGHSRGLAGNRHRGPD2GRIN1GRIN2AGRIN2BGRIN2CGRIN2DGRIN3AGRIN3BGSTP1HCN4HCRTR1HCRTR2HDAC1HDAC10HDAC11HDAC2HDAC3HDAC4HDAC5HDAC6HDAC7HDAC8HDAC9HRH1HRH2HRH3HSD11B1HSP90AA1HSP90AB1HTR1AHTR1BHTR1DHTR1EHTR1FHTR2AHTR2BHTR2CHTR3AHTR3BHTR3CHTR3DHTR3EHTR4HTR5AHTR6HTR7IMPDH1IMPDH2ITGA2BITGB3ITKJAK1JAK2KCNA1KCNA10KCNA2KCNA3KCNA4KCNA5KCNA6KCNA7KCNB1KCNB2KCNC1KCNC2KCNC3KCNC4KCND1KCND2KCND3KCNF1KCNG1KCNG2KCNG3KCNG4KCNH1KCNH2KCNH3KCNH4KCNH5KCNH6KCNH7KCNH8KCNJ2KCNJ3KCNJ5KCNK3KCNK9KCNQ1KCNQ2KCNQ3KCNQ4KCNQ5KCNS1KCNS2KCNS3KCNV1KCNV2KDRKITKLKB1LCKMMAOAMAOBMAPK14METMMP1MMP13MMP7MMP8MT-ND1MT-ND2MT-ND3MT-ND4MT-ND4LMT-ND5MT-ND6NDUFA1NDUFA10NDUFA11NDUFA12NDUFA13NDUFA2NDUFA3NDUFA5NDUFA6NDUFA7NDUFA8NDUFA9NDUFAB1NDUFAF1NDUFAF2NDUFAF3NDUFAF4NDUFB1NDUFB10NDUFB11NDUFB2NDUFB3NDUFB4NDUFB5NDUFB6NDUFB7NDUFB8NDUFB9NDUFC1NDUFC2NDUFS1NDUFS2NDUFS3NDUFS4NDUFS5NDUFS6NDUFS7NDUFS8NDUFV1NDUFV2NDUFV3NR3C1NS5ANTRK1NTRK2NTRK3ODC1OPRD1OPRK1OPRM1P2RY12PAHPARP1PDE3APDE3BPDE4APDE4BPDE4CPDE4DPDE5APDE7APDE7BPDE8APDE8BPDGFRAPDGFRBPIK3CAPIK3CDPNPPOLA1POLA2POLD1POLD2POLD3POLD4POLEPOLE2POLE3PPARGPRIM1PRIM2PRKCAPRKCBPRKCDPRKCEPRKCGPRKCHPRKCIPRKCQPRKCZPRKD1PRKD3PTGS1PTGS2RBX1RENRETROCK1ROCK2RPE65RRM1RRM2RRM2BS1PR1S1PR2S1PR3S1PR4S1PR5SCN10ASCN11ASCN1ASCN2ASCN3ASCN4ASCN5ASCN7ASCN8ASCN9ASCNN1ASCNN1BSCNN1GSIGMAR1SLC18A2SLC6A1SLC6A2SLC6A3SLC6A4SLC9A3SRCTACR1TOP1TOP2ATOP2BTTRTYMPdacAdacBdacCembAfolAftsIgyrAgyrBmrcAmrcBmrdAparCparEpolrplArplBrplCrplDrplErplFrplIrplJrplKrplLrplMrplNrplOrplPrplQrplRrplSrplTrplUrplVrplWrplXrplYrpmArpmBrpmCrpmDrpmErpmE2rpmFrpmGrpmG1rpmG2rpmG3rpmHrpmIrpmJrpsArpsBrpsCrpsDrpsErpsFrpsGrpsHrpsIrpsJrpsKrpsLrpsMrpsNrpsOrpsPrpsQrpsRrpsSrpsTrpsUykgMykgO
The experimentally established mechanism targets of Hydrochloric Acid. The predicted profile below is derived independently by chemical similarity — agreement is a validation signal, a miss is honest.
Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CHRNB4 known ✓ | P30926 | 1/20 | 0.52 |
| ▸ | CHRNA3 known ✓ | P32297 | 1/20 | 0.52 |
| ▸ | CHRNA7 known ✓ | P36544 | 1/20 | 0.52 |
| ▸ | GABRP known ✓ | O00591 | 1/20 | 0.41 |
| ▸ | GABRD known ✓ | O14764 | 1/20 | 0.41 |
| ▸ | GABRA1 known ✓ | P14867 | 1/20 | 0.41 |
| ▸ | GABRB1 known ✓ | P18505 | 1/20 | 0.41 |
| ▸ | GABRG2 known ✓ | P18507 | 1/20 | 0.41 |
| ▸ | GABRB3 known ✓ | P28472 | 1/20 | 0.41 |
| ▸ | GABRA5 known ✓ | P31644 | 1/20 | 0.41 |
| ▸ | GABRA3 known ✓ | P34903 | 1/20 | 0.41 |
| ▸ | GABRA2 known ✓ | P47869 | 1/20 | 0.41 |
| ▸ | GABRB2 known ✓ | P47870 | 1/20 | 0.41 |
| ▸ | GABRA4 known ✓ | P48169 | 1/20 | 0.41 |
| ▸ | GABRE known ✓ | P78334 | 1/20 | 0.41 |
| ▸ | GABRA6 known ✓ | Q16445 | 1/20 | 0.41 |
| ▸ | GABRG1 known ✓ | Q8N1C3 | 1/20 | 0.41 |
| ▸ | GABRG3 known ✓ | Q99928 | 1/20 | 0.41 |
| ▸ | GABRQ known ✓ | Q9UN88 | 1/20 | 0.41 |
| ▸ | SLC6A1 known ✓ | P30531 | 2/20 | 0.41 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| Hydrochloric Acid SCHEMBL594534 | 1.00 | CHRNB2 (0.52) | CHRNB2CHRNA4CHRNB4CHRNA3CHRNA7 | |
| Hydrochloric Acid SCHEMBL3911969 | 1.00 | CHRNB2 (0.52) | CHRNB2CHRNA4CHRNB4CHRNA3CHRNA7 | |
| SCHEMBL1161879 | 0.98 | — | — | |
| SCHEMBL584094 | 0.98 | — | — | |
| SCHEMBL12699753 | 0.98 | — | — | |
| Methane SCHEMBL10516513 | 0.96 | CHRNB2 (0.52) | CHRNB2CHRNA4CHRNB4CHRNA3CHRNA7 | |
| Acetic Acid Methyl Ester SCHEMBL9148923 | 0.92 | CHRNB2 (0.48) | CHRNB2CHRNA4CHRNB4CHRNA3CHRNA7 | |
| Hydrochloric Acid SCHEMBL21224938 | 0.88 | SLC6A1 (0.57) | CHRNB2CHRNA4CHRNB4CHRNA3CHRNA7 | |
| Hydrochloric Acid SCHEMBL30493397 | 0.88 | SLC6A1 (0.57) | CHRNB2CHRNA4CHRNB4CHRNA3CHRNA7 | |
| Hydrochloric Acid SCHEMBL28798276 | 0.88 | SLC6A1 (0.57) | CHRNB2CHRNA4CHRNB4CHRNA3CHRNA7 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 65 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-4651872-A1 | COMPOUNDS, COMPOSITIONS AND METHODS OF USE TO TREAT HYPOPARATHYROIDISM AND OSTEOPOROSIS | Septerna, Inc. (US) | 2025-11-26 | — | — | EP | disclosed |
| WO-2025228947-A1 | BIFUNCTIONAL COMPOUNDS CAPABLE OF INDUCING DEGRADATION OF POLO-LIKE KINASE1 | CROSSFIRE ONCOLOGY B.V. (NL) | 2025-11-06 | — | — | WO | disclosed |
| US-20250154145-A1 | OXER1 ANTAGONISTS AND USES THEREOF | GREEN CHEMISTRY CONSULTING LLC | 2025-05-15 | — | — | US | disclosed |
| WO-2025049326-A1 | TRICYCLIC HETEROAROMATIC INHIBITORS OF KLK5 | BIOCRYST PHARMACEUTICALS, INC. (US) | 2025-03-06 | — | — | WO | disclosed |
| US-20250034132-A1 | PROLYL HYDROXYLASE DOMAIN-CONTAINING PROTEIN (PHD) INHIBITORS AND USES THEREOF | INSILICO MEDICINE IP LIMITED (HK) | 2025-01-30 | — | — | US | disclosed |
| US-12195447-B2 | Azolopyrimidine for the treatment of cancer-related disorders | ARCUS BIOSCIENCES, INC. (US) | 2025-01-14 | — | — | US | disclosed |
| US-20240391875-A1 | ISOQUINOLINONES AND QUINOLINONES AS MODULATORS OF POLRMT | PRETZEL THERAPEUTICS, INC. (US) | 2024-11-28 | — | — | US | disclosed |
| EP-4452940-A1 | OXER1 ANTAGONISTS AND USES THEREOF | Fairhaven Pharmaceuticals Inc. (CA) | 2024-10-30 | — | — | EP | disclosed |
| WO-2024179529-A1 | SUBSTITUTED TRICYCLIC DERIVATIVE, AND PHARMACEUTICAL COMPOSITION AND USE THEREOF | 上海海雁医药科技有限公司 | 2024-09-06 | — | — | WO | disclosed |
| EP-4423074-A1 | PROLYL HYDROXYLASE DOMAIN-CONTAINING PROTEIN (PHD) INHIBITORS AND USES THEREOF | Insilico Medicine IP Limited (HK) | 2024-09-04 | — | — | EP | disclosed |
| US-10208048-B2 | RSV antiviral pyrazolo- and triazolo-pyrimidine compounds | JANSSEN SCIENCES IRELAND UC (IE) | 2019-02-19 | — | — | US | disclosed |
| US-20180215730-A1 | AZOLOPYRIMIDINE FOR THE TREATMENT OF CANCER-RELATED DISORDERS | ARCUS BIOSCIENCES, INC. | 2018-08-02 | — | — | US | disclosed |
| CN-105051037-B | Sphingosine-1-phosphate receptor agonists, method for the preparation thereof and pharmaceutical compositions comprising the same as active agent | LG化学株式会社 | 2018-05-18 | — | — | CN | disclosed |
| US-20180105529-A1 | RSV ANTIVIRAL PYRAZOLO- AND TRIAZOLO-PYRIMIDINE COMPOUNDS | JANSSEN SCIENCES IRELAND UC (IE) | 2018-04-19 | — | — | US | disclosed |
| EP-3288942-A1 | RSV ANTIVIRAL PYRAZOLO- AND TRIAZOLO-PYRIMIDINE COMPOUNDS | Janssen Sciences Ireland UC (IE) | 2018-03-07 | — | — | EP | disclosed |
| CN-107531715-A | The antiviral pyrazolos of RSV and triazolopyrimidine compound | 爱尔兰詹森科学公司 | 2018-01-02 | — | — | CN | disclosed |
| US-9540362-B2 | Sphingosine-1-phosphate receptor agonists, methods of preparing the same, and pharmaceutical compositions containing the same as an active agent | LG LIFE SCIENCES LTD. (KR) | 2017-01-10 | — | — | US | disclosed |
| WO-2016174079-A1 | RSV ANTIVIRAL PYRAZOLO- AND TRIAZOLO-PYRIMIDINE COMPOUNDS | JANSSEN SCIENCES IRELAND UC (IE) | 2016-11-03 | — | — | WO | disclosed |
| US-20150376173-A1 | SPHINGOSINE-1-PHOSPHATE RECEPTOR AGONISTS, METHODS OF PREPARING THE SAME, AND PHARMACEUTICAL COMPOSITIONS CONTAINING THE SAME AS AN ACTIVE AGENT | LG LIFE SCIENCES LTD. (KR) | 2015-12-31 | — | — | US | disclosed |
| CN-101877966-A | Farnesoid X receptor agonists | SMITHKLINE BEECHAM CORP | 2010-11-03 | — | — | CN | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (8 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20240391875-A1 | ISOQUINOLINONES AND QUINOLINONES AS MODULATORS OF POLRMT | POLRMT, TFAM, POLM | CHRNB4 4248/4885CHRNA3 3989/4885CHRNA7 3828/4885 |
| US-20250034132-A1 | PROLYL HYDROXYLASE DOMAIN-CONTAINING PROTEIN (PHD) INHIBITORS AND USES THEREOF | EGLN3, EGLN2, EGLN1 | CHRNB4 4866/4885CHRNA3 4836/4885CHRNA7 4870/4885 |
| US-20150376173-A1 | SPHINGOSINE-1-PHOSPHATE RECEPTOR AGONISTS, METHODS OF PREPARING THE SAME, AND PHARMACEUTICAL COMPOSITIONS CONTAINING THE SAME AS AN ACTIVE AGENT | S1PR1, S1PR2, S1PR5 | CHRNB4 987/4885CHRNA3 826/4885CHRNA7 393/4885 |
| US-10208048-B2 | RSV antiviral pyrazolo- and triazolo-pyrimidine compounds | ZC3HAV1, MAVS, TYMP | CHRNB4 4792/4885CHRNA3 4810/4885CHRNA7 4799/4885 |
| US-12195447-B2 | Azolopyrimidine for the treatment of cancer-related disorders | ADORA2A, ADORA2B, ADORA1 | CHRNB4 4099/4885CHRNA3 4232/4885CHRNA7 4264/4885 |
| US-20180105529-A1 | RSV ANTIVIRAL PYRAZOLO- AND TRIAZOLO-PYRIMIDINE COMPOUNDS | ZC3HAV1, MAVS, TYMP | CHRNB4 4792/4885CHRNA3 4810/4885CHRNA7 4799/4885 |
| US-20250154145-A1 | OXER1 ANTAGONISTS AND USES THEREOF | OXER1, OXGR1, OXTR | CHRNB4 305/4885CHRNA3 254/4885CHRNA7 415/4885 |
| US-20180215730-A1 | AZOLOPYRIMIDINE FOR THE TREATMENT OF CANCER-RELATED DISORDERS | ADORA2A, ADORA2B, ADORA1 | CHRNB4 4099/4885CHRNA3 4232/4885CHRNA7 4264/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.